Halil BAŞAR, Aykut DEMİRCİ

Artan prostat hacmi erektil fonksiyon ve yaşam kalitesi için bir risk faktörü müdür?

AMAÇ: Benign prostat hiperplazisi (BPH) yaşlanan erkeklerde en sık alt üriner sistem semptomları (AÜSS) nedenidir. Prostat hacmi (PH) BPH’nin progresyonunu göstermesi açısından önemlidir. BPH hastalarında erektil disfonksiyon (ED) sık görülmektedir. Biz de artan prostat hacminin BPH hastalarının erektil fonksiyonunu ve yaşam kalitesini (QoL) nasıl etkilediğini araştırmayı amaçladık. GEREÇ ve YÖNTEMLER: Mayıs-Ağustos 2022 tarihleri arasında klini- ğimizde BPH tanısı alan 154 hasta çalışmaya alınmıştır. Prostat hacmi 30–50 cc olanlar Grup 1 (s=74), 50–80 cc olanlar Grup 2 (s=58), >80 cc olanlar Grup 3 (s=22)’e dâhil edilmiştir. Hastaların IPSS (Uluslararası Prostat Semptom Skoru) ve IIEF-5 (Uluslararası Erektil İşlev Formu-5) anketinde almış oldukları puanlar kaydedilmiştir. Uluslararası Prostat Semptom Skoru anketinde 8. Soruya [“Hayatınızın bundan sonraki bölümünde şikâyetleriniz aynen devam ederse kendinizi nasıl hissedersiniz?” 0 (Çok Mutlu) - 6 (Berbat)] verilen skor ile hastaların QoL’ı değerlendirilmiştir. BULGULAR: Erektil disfonksiyon tüm hastaların %76,6 (s=118)’sında tespit edildi. Grup 1’deki hastaların Grup 3’tekilere göre daha genç oldu- ğu görüldü (61,6±6,77 vs. 66,1±6,37, p=0,04, sırasıyla). Diğer gruplara göre Grup 1’de median IPSS[15 (11,5) vs. Grup 2, 18 (13), p=0,006; Grup 3, 21 (12), p=0,012] ve QoL [3 (2,25) vs. Grup 2, 4 (2), p=0,012; Grup 3, 4 (2), p=0,03] skorlarının düşük olduğu, median IIEF-5 [21 (6,25) vs. Grup 2, 11,5 (5,75); Grup 3, 5 (1), p

Is increased prostate volume a risk factor for erectile function and quality of life?

OBJECTIVE: Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptoms (LUTS) in aging men. Prostate volume (PV) is important in showing the progression of BPH. Erectile dysfunction (ED) is common sexual problem in BPH patients. We aimed to investigate how increased prostate volume affects the erectile function and quality of life (QoL) of the BPH patients. MATERIAL and METHODS: Between May and August 2022, 154 patients diagnosed with BPH in our clinic were included in the study. Those with a PV of 30–50 cc were included in Group 1 (n=74), those with 50–80 cc in Group 2 (n=58), and those with >80 cc in Group 3 (n=22). The scores of the patients in the IPSS (International Prostate Symptom Score) and IIEF-5 (International Erectile Function Form-5) questionnaires were recorded. The QoL of the patients was evaluated with the scores given the 8th question in the IPSS questionnaire [“How would you feel if your complaints continued in the rest of your life?” 0 (Delighted) - 6 (Terrible)]. RESULTS: ED was detected in 76.6% (n=118) of all patients. It was observed that the patients in Group 1 were younger than Group 3 (61.6±6.77 vs. 66.1±6.37, p=0.04, respectively). Compared to the other groups, it was observed that the median IPSS [15 (11.5) vs. Group 2, 18 (13), p=0.006; Group 3, 21 (12), p=0.012] and QoL scores [3 (2.25) vs. Group 2, 4 (2), p=0.012; Group 3, 4 (2), p=0.03] were lower, and the median IIEF-5 score [21 (6.25) vs. Group 2, 11.5 (5.75); Group 3, 5 (1), p

PDF

___

1. Kupelian V, Wei JT, O’Leary MP, Kusek JW, Litman HJ, Link CL, et al.;BACH Survery Investigators. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006;166:2381–7. [CrossRef]
2. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43:289–97. [CrossRef]
3. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22 Suppl 1:1–6.
4. Mc Connell JD. The long term effects of medical therapy on the progression of BPH. Results from the MTOPS trial. J Urol. 2002;167:265, abstract 1042.
5. Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA, Lieber MM. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol. 1995;153:1510–5. [CrossRef]
6. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83–90. https://pubmed.ncbi.nlm.nih.gov/8510302/
7. Seftel AD, de la Rosette J, Birt J, Porter V, Zarotsky V, Viktrup L. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract. 2013;67:32–45. [CrossRef]
8. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637–49. [CrossRef]
9. Rouprêt M, Seisen T, De La Taille A, Desgrandchamps F. Troubles sexuels associés aux maladies de la prostate [Sexual dysfunctions linked with prostatic diseases]. Prog Urol. 2012;22 Suppl 1:S14– 20. French. [CrossRef]
10. Calogero AE, Burgio G, Condorelli RA, Cannarella R, La Vignera S. Epidemiology and risk factors of lower urinary tract symptoms/ benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2019;22:12–19. [CrossRef]
11. Bouwman II, Van Der Heide WK, Van Der Meer K, Nijman R. Correlations between lower urinary tract symptoms, erectile dysfunction, and cardiovascular diseases: are there differences between male populations from primary healthcare and urology clinics? A review of the current knowledge. Eur J Gen Pract. 2009;15:128–35. [CrossRef]
12. Green JS, Holden ST, Bose P, George DP, Bowsher WG. An investigation into the relationship between prostate size, peak urinary flow rate and male erectile dysfunction. Int J Impot Res. 2001;13:322–5. [CrossRef]
13. Cockett A, Aso Y, Denis L. Prostate symptom score and quality of life assessment. In: Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G, editors. Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH); 27–30 June. 1993; Paris; Channel Island, Jersey: Scientific Communication International; 1994. pp. 553–5.
14. Bozlu M, Doruk E, Akbay E, Ulusoy E, Cayan S, Acar D, Emíne Kanik A. Effect of administration mode (patient vs physician) and patient’s educational level on the Turkish version of the International Prostate Symptom Score. Int J Urol. 2002;9:417–21. [CrossRef]
15. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5)as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–26. [CrossRef]
16. Turunç T, Deveci S, Güvel S, Peşkircioğlu, L. The assessment of Turkish validation with 5 question version of International Index of Erectile Function (IIEF-5). Turk J Urol. 2007;33:45–9. https://www.researchgate.net/publication/283773629_The_ assessment_of_Turkish_validation_with_5_question_version_of_ International_Index_of_Erectile_Function_IIEF-5
17. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al.;Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78. [CrossRef]
18. Braun M, Wassmer G, Klotz T, Reinfenrath B, Mathers M, Engelman U. Epydemiological study of ED. results of the ‘Cologne Male Survey’. Int J Impot Res. 2000;12:305–11. [CrossRef]
19. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. European Association of Urology. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–40. [CrossRef]
20. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96:1339–54. [CrossRef]
21. Kardasevic A, Milicevic S. The Correlation Between Prostate Volume in Patients with Benign Prostatic Hyperplasia in Relation to Erectile Dysfunction. Med Arch. 2016;70:449–52. [CrossRef]
22. Wu C-J, Hsieh J-T, Lin JS-N, Hwang TI-S, Jiann B-P, Huang S-T, et al. Comparison of prevalence between self-reported erectile dysfunction and erectile dysfunction as defined by five-item International Index of Erectile Function in Taiwanese men older than 40 years. Urology. 2007;69:743–7. [CrossRef]
23. Bayraktar Z, Atun I. Prevalence of self-reported erectile dysfunction among urological cases in Turkish men. Urol J. 2011;8:214–21. https://pubmed.ncbi.nlm.nih.gov/21910101/
24. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA; BPH Registry and Patient Survey Steering Committee. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology. 2009;73:562–6. [CrossRef]
25. Corona G, Gacci M, Maseroli E, Rastrelli G, Vignozzi L, Sforza A, et al. Clinical correlates of enlarged prostate size in subjects with sexual dysfunction. Asian J Androl. 2014;16:767–73. [CrossRef ]